Related Experiment Video
Updated: Aug 14, 2026
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
The clinical course of acquired aplastic anemia in childhood; a retrospective study
1Department of Pediatrics, Yokohama City University School of Medicine, Japan.
Insights
This study on pediatric acquired aplastic anemia (AA) found that while severity criteria are useful, even mild cases need monitoring. Early intervention with cytokine therapy is recommended for severe AA without transplant donors.
Area of Science:
- Pediatric Hematology
- Bone Marrow Failure Syndromes
- Aplastic Anemia Research
Background:
- Acquired aplastic anemia (AA) in children presents a significant clinical challenge.
- Accurate prognostic criteria are crucial for guiding treatment decisions in pediatric AA.
Purpose of the Study:
- To evaluate the clinical course and treatment outcomes of pediatric acquired aplastic anemia.
- To assess the utility of the Japanese Ministry of Health and Welfare (JMHW) Study Group severity criteria.
- To explore effective therapeutic strategies for severe pediatric AA.
Main Methods:
- Retrospective review of clinical data from 38 children with acquired aplastic anemia.
- Classification of patients based on JMHW Study Group severity criteria (severe, moderate, mild).
- Analysis of treatment responses to corticosteroids, anabolic steroids, allogeneic bone marrow transplant (BMT), and cytokine therapy (rhG-CSF, rhEPO).
Main Results:
- Early death occurred exclusively in severe AA cases; however, non-severe cases could progress to severe.
- Long-term survival rates did not significantly differ between initially non-severe and severe AA.
- Hematological recovery was observed in 16/33 patients treated with corticosteroids and/or anabolic steroids.
- Trilineage recovery was achieved in 3/6 patients receiving cytokine therapy (rhG-CSF and rhEPO), with sustained hematopoiesis in 2 cases.
- Patients with higher bone marrow lymphocyte frequency and lower peripheral neutrophil counts who died within a year indicated a very severe prognosis.
Conclusions:
- The JMHW Study Group criteria are valuable for identifying pediatric AA patients with a poor prognosis, but continuous evaluation of non-severe cases is essential.
- Combination therapy with cytokines (rhG-CSF and rhEPO) is a promising treatment option for severe pediatric AA patients lacking a sibling donor for BMT.
- Further research into optimal treatment strategies for pediatric aplastic anemia is warranted.
Abstract:
We reviewed the clinical courses of 38 children with acquired aplastic anemia (AA). The patients were classified according to the severity criteria by the Japanese Ministry of Health and Welfare (JMHW) Study Group (22 severe, 15 moderate, 1 mild). Early death was observed only in severe cases. Eight of the non-severe cases progressed to severe in 0.5-125 months, and the long-term survival rate of non-severe AA did not differ from that of severe AA. The frequency of lymphocytes in the bone marrow was significantly higher, and the peripheral blood neutrophil count was lower in patients who died within a year, and these patients should be treated as very severe. These findings suggest that the JMHW Study Group criteria are useful for identifying AA patients with a poor prognosis, but even non-severe cases should be repeatedly evaluated. Sixteen of the 33 patients treated with corticosteroids and/or anabolic steroids (AS) showed hematological recovery. Bolus methylprednisolone (mPSL) therapy was effective in one of the 8 patients. Allogenic marrow transplant (BMT) was performed on 3 patients. One died from sepsis and engraftment was not achieved in the other two. Trilineage recovery was obtained in 3 of 6 patients treated with rhG-CSF and rhEPO with or without AS, and hemopoiesis has been maintained 6-12 months after discontinuation in 2 cases. In the other 3 patients, the neutrophil count showed transient increase. Therefore, the treatment for severe AA patients, who have no sibling donor for BMT, should be started with the combination therapy including these cytokines.
